THDP17 decreases ammonia production through glutaminase inhibition. A new drug for hepatic encephalopathy therapy by Iglesias Guerra, Fernando et al.
THDP17 Decreases Ammonia Production through
Glutaminase Inhibition. A New Drug for Hepatic
Encephalopathy Therapy
M. Mar Dı´az-Herrero1., Jose´ A. del Campo2., Pilar Carbonero-Aguilar1, Jose´ M. Vega-Pe´rez3,
Fernando Iglesias-Guerra3, Ignacio Perin˜a´n3, Francisco J. Min˜ano4, Juan Bautista1*, Manuel Romero-
Go´mez2*
1Departamento de Bioquı´mica y Biologı´a Molecular, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain, 2Unidad de Gestio´n Clı´nica de Enfermedades Digestivas
& Centro de Investigacio´n Biome´dica en Red de Enfermedades Hepa´ticas y Digestivas (CIBERehd), Hospital Universitario de Valme, Sevilla, Spain, 3Departamento de
Quı´mica Orga´nica y Quı´mica Farmace´utica, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain, 4Unidad de Farmacologı´a Experimental y Clı´nica (UFEC), Hospital
Universitario de Valme, Universidad de Sevilla, Sevilla, Spain
Abstract
Ammonia production is implicated in the pathogenesis of hepatic encephalopathy (HE), being intestinal glutaminase
activity the main source for ammonia. Management of ammonia formation can be effective in HE treatment by lowering
intestinal ammonia production. The use of glutaminase inhibitors represents one way to achieve this goal. In this work, we
have performed a search for specific inhibitors that could decrease glutaminase activity by screening two different groups
of compounds: i) a group integrated by a diverse, highly pure small molecule compounds derived from thiourea ranging
from 200 to 800 Daltons; and ii) a group integrated by commonly use compounds in the treatment of HE. Results shown
that THDP-17 (10 mM), a thiourea derivate product, could inhibit the intestinal glutaminase activity (57.466.7%). Inhibitory
effect was tissue dependent, ranging from 4065.5% to 8067.8% in an uncompetitive manner, showing Vmax and Km values
of 384.62 mmol min21, 13.62 mM with THDP-17 10 mM, respectively. This compound also decreased the glutaminase
activity in Caco-2 cell cultures, showing a reduction of ammonia and glutamate production, compared to control cultures.
Therefore, the THDP-17 compound could be a good candidate for HE management, by lowering ammonia production.
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Introduction
Ammonia plays a major role in the pathogenesis of hepatic
encephalopathy (HE). Systemic hyperammonemia has been
largely found in patients with cirrhosis and HE. Ammonia derived
from the gut and kidneys must be detoxified in the liver and
muscle. In cirrhotic patients with impaired capacity for detoxifi-
cation of ammonia into urea, peripheral glutamine synthase
(mainly in muscle tissue) serves as the main alternative for
ammonia detoxification pathway. In the brain, hyperammonemia
promotes astrocyte swelling and impairment of neurotransmission
[1,2]. In muscle tissue, it has been shown that glutaminase activity
is increased in an animal model undergoing bile duct ligation and
glutamine synthase has been shown to have an important role in
detoxification of plasma ammonia in acute liver failure [3].
Moreover, the development of portosystemic shunting and
alteration of blood flow is thought to affect circulating ammonia
levels in cirrhosis [4]. These findings suggest that approaches to
target glutaminase (by inhibition) may provide targets for
ammonia detoxification as a valid therapeutic strategy for HE.
Glutamine deamidation by intestinal GA has been proposed as
one of the main sources of ammonia production in patients with
cirrhosis [5]. However, hyperammonemia found after portacaval
shunt in rats is similar in both germ-free and non-germ-free
animals [6,7] supporting the hypothesis that hyperammonemia
and encephalopathy can be developed without the participation of
bacteria [8].
Another supporting evidence is that the greatest hyperammo-
nemia has been found in portal-drained viscera and derived
mainly from glutamine deamidation in cirrhotic patients by
phosphate-activated glutaminase (PAG) [9,10]. Glutamine synthe-
sis is an effective mechanism to reduce the levels of ammonia;
however, much of the newly synthesized glutamine is subsequently
metabolized in mitochondria by phosphate-activated glutaminase,
yielding glutamate and ammonia. In this manner, glutamine (the
Trojan horse) is transported in excess from the cytoplasm to
mitochondria serving as a carrier of ammonia [11].
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PAG catalyzes the deamidation of glutamine to yield glutamate
and ammonia. There are two genes that encoding two main
isoforms of PAG: the kidney-type PAG (K-PAG) and the hepatic-
type PAG (L-PAG). The K-PAG is the ubiquitous form. It can be
found in kidney, brain, stomach, pancreas, muscle, or villus
enterocyte; while L-PAG was thought to be restricted to the liver
but in the last years it has also been found in nuclei of mammalian
brain [12], and granule in human neutrophils [13]. The presence
of LGA and/or KGA, together with GAC (Glutaminase C) form
has also been reported in different tumour cells [14–16].
In healthy people, the higher PAG activity along the
gastrointestinal tract has been found in the small intestine, being
higher than 80% of the activity [17]. Lower but still substantial
activity was found in the large intestine, approximately the 15%.
In rats, the distribution of the PAG activity was found to be similar
to humans [18]. Duodenal PAG activity, measured in mucosal
biopsies from the first portion of the small intestine, has been
found to be nearly four-times higher in cirrhotic patients than in
healthy controls [10].
As the main source of ammonia in cirrhotic patients derives
from portal-drained viscera owing to glutamine deamidation, PAG
activity in the intestine seems to be responsible, largely, for
systemic hyperammonemia production in these patients [5].
Besides, in portacaval shunted rats, a model for minimal HE
[19], PAG activity has been found to be increased in duodenum
and ileum compared to sham-operated rats [20]. All these data
suggest that PAG is implicated in the production of systemic
hyperammonemia from the intestine and could play a major role
in the pathogenesis of HE. Therefore, a decrease of ammonia
production in the small intestine by PAG inhibition may
contribute to lower ammonia concentration in the systemic
circulation. The aim of this work was the search for glutaminase
inhibitors in order to find new ammonia-lowering drugs that could
be used in the management of HE.
Materials and Methods
All chemicals used in this work were from high analytical grade
and were obtained mainly from Sigma-Aldrich.
Compounds
Two groups of compounds were used:
The first group was integrated by a collection of diverse, highly
pure, small molecule compounds derived from thiourea ranging
from 200 to 800 Daltons. These compounds were named as
THDP-xx, being xx an assigned number to each product.
Compounds were received as powder and then dissolved in
dimethyl sulfoxide (DMSO) to constitute a 10 mM stock
concentration and stored at 220uC. Maximum DMSO concen-
tration in the reaction mixture was 0.5% (vol/vol) to avoid toxic
effects. Most of the compounds in the library can be dissolved at
50 mg/ml. For those compounds that did not dissolve (,5%),
concentration was decreased to 10–25 mg/ml. All compounds
were synthesized at the Departamento de Quı´mica Orga´nica y
Farmace´utica of Universidad de Sevilla (Spain) [21–23] as the
result for a new simple thiourea derivatives library with potential
use as enzymatic inhibitors.
The second group was integrated by compounds used or tested
for the treatment of HE: metformine, metronidazole, neomicine,
rifaximin, lactulose and lactitol (all purchased from Sigma-
Aldrich).
In vitro inhibition screening
PAG inhibition analysis by different thiourea derivatives
(THDP) was assayed in vitro, using the method of Heini for
glutaminase activity determination [24], adapted to a microtiter
procedure. This assay is based on the use of o-phthaldialdehyde/
mercaptoethanol as a reagent for estimating ammonia released
from glutamine. Briefly, 25 ml samples were added to 35 ml of a
mixture of 150 mM potassium phosphate, 171 mM glutamine,
1 mM ammonium chloride, pH 8.0 and then incubated at 37uC
for 45 min. The reaction was stopped by adding 10 ml 7%
trichloroacetic acid, kept on ice for 15 min and centrifuged 5 min
at 10006g. Aliquots of 5 ml/well were then mixed with 150 ml o-
phthalaldehyde/mercaptoethanol reagent (14.4 ml 200 mM po-
tassium phosphate, pH 7.4, 0.8 ml 72 mM mercaptoethanol in
ethanol and 0.8 ml 186 mM o-phthaldialdehyde in ethanol). The
samples were kept at room temperature in the dark and
absorbance measured at 410 nm with a UV-Visible spectropho-
tometer (BioRad) after 45 min.
Kinetic assays
K-PAG activity was assayed, in presence and absence of the
inhibitor; using isolated mitochondria from rat intestine and
kidney, solubilized with 1% Triton X-100 as a source of
glutaminase [25]. Enzymatic activity was measured using a two-
step assay as described by Lund [26]. Protein concentration was
Figure 1. Inhibitory effect on glutaminase activity of several compounds tested in this study. Data are shown in log scale (inhibitor
concentration), being 100% activity measured without inhibitor. There was not significant differences among compounds tested (Student t test; p.
0.05). THDP-17 was chosen on toxic effect base.
doi:10.1371/journal.pone.0109787.g001
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determined following Bradford method using serum albumin as
standard [27].
Cell culture
Caco2 cells were purchased from Sigma-Aldrich (St. Louis,
MO, USA) and grown with DMEM (Dulbecco’s Modified Eagle
Medium) medium supplemented with 2 mM L-Glutamine, 15%
FBS, 1X antinbiotic/antimicotic solution, 1X non-essential amino
acids (PAA Laboratories GmbH, Linz, Germany). Cells were
incubated at 37uC and 5% CO2.
Cytotoxicity assay
Cytotoxicity was evaluated in Caco-2 cells after 24 h-exposure
to selected inhibitors using neutral red (NR) assay (Zhang et al.
1990) [28]. Regression analysis of dose-response curves and
calculation of IC50 were done according to standard procedure
using appropriated software.
Inhibition assay in cell culture
Inhibition assay was carried out by measuring the concentration
of glutamate produced from glutamine by Caco-2 cells using
HPLC, in presence and absence of the selected inhibitor (THDP-
17) at different concentrations (0, 5, 20 and 100 mM) and time
points (24 and 48 h). 6-Diazo-5-oxo-L-norleucine (DON) (0–
100 mM) was used as positive control. The presence of the THDP-
17 in the cells was checked by HPLC-MS.
Lethal Dose 50
Lethal dose was determined by oral administration of the
compounds to C57BL/6 mice. Thirty mice were supplied by the
Centre of Production and Experimental animal of Espartinas,
University of Seville, Spain. The animals were housed ten per
cage, and maintained at constant room temperature (22uC 62uC),
with artificial light-dark cycle of 12 h and a relative humidity of
65%270%, and free access to food and water during 2 weeks for
acclimation. All animal procedures were performed with approval
from the Sevilla University Animal Ethics Committees, under the
Figure 2. Molecular structure of N-(3-methyl 3-butenyl)-N9 phenyl thiourea (THDP17).
doi:10.1371/journal.pone.0109787.g002
Figure 3. THDP17 inhibition kinetics. A lineal double reciprocal plot (1/v against 1/[Gln]) in absence (0) and presence (10 mM) of the
inhibitor is shown. Vmax and KM values for PAG were 0.67 mmol min
21, and 19.33 mM, respectively. In the presence of THDP-17 both parameters
were modified: Vmax-ap = 0.38 mmol min
21, and KM-ap = 13.62 mM, indicating an uncompetitive inhibition. All experiments were performed in
triplicates; p.0.05.
doi:10.1371/journal.pone.0109787.g003
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guidelines of the directive 86/609/CEE of the European Union.
Two assays in different conditions were performed. In the first
assay fasted mice were divided in four groups of three animals and
were administered 0, 50, 300 or 2000 mg THDP-17/kg,
respectively. They were sacrificed 24 h latter and a macroscopic
analysis of the tissues (lungs, heart, liver, stomach and intestine)
was performed. In the second assay the mice were feed ad libitum,
separated into three groups of four animals per group and
administered them 0, 5 or 300 mg THDP-17/kg, respectively. In
this case, mice were sacrificed 24 or 72 h latter and the same
macroscopic analysis was performed.
Statistical analysis
The results were expressed as means and standard deviations (or
standard errors) of three independent experiments. The results
were analyzed with the Student t test. P,0.001, P,0.01, and P,
0.05 were considered statistically significant.
Results and Discussion
Ammonia-lowering drugs have received great interest in the
management of HE in the last few years. In order to develop
adequate and selective inhibitors of intestinal PAG activity, we
performed a screening of three different groups of compounds: i) a
group integrated by a collection of diverse, highly pure, rationally
selected small molecule compounds derived from thiourea ranging
from 200 to 800 Daltons; ii) a group integrated by products
showing some structural analogy with the compound THDP-17,
and iii) a group integrated by compounds usually used in the
treatment of HE.
i) Thiourea derived products
The first group analysed in this work is integrated by a small
molecule compounds library derived from thiourea [21]. We
found that some products derived from thiourea were able to
reduce ammonia production in vitro from glutamine by an
enriched preparation of glutaminase obtained from both kidney
and intestine mitochondria (data not shown). For the screening, we
have used the Heini’s method to assay the glutaminase activity. Six
synthetic inhibitors derived from thiourea were selected and
extensively characterized. These products (THDP-17, THDP-33,
THDP-39, THDP-41, THDP-42, and THDP-43) could inhibit K-
PAG activity and were tested for toxicity and grade of inhibition
on a cell culture based method, using the neutral red (NR) assay.
- Effects of selected inhibitors on cytotoxicity. Acute
toxicity test in animals is typically the first step in the evaluation of
the effects of a chemical compound, and its primary purpose is to
provide information on potential health hazards that may result
from a short-term exposure. Recent studies suggest that in vitro
methods might be helpful in predicting acute toxicity and
estimating toxic chemical concentrations in vivo [29]. In the
Figure 4. In vivo inhibitory effect on glutaminase activity at different concentrations of THDP17 and DON (6-Diazo-5-oxo-L-
norleucine) was tested in Caco-2 cell cultures. PAG inhibition by THDP-17 in cell cultures is effective at concentration higher than 5 mM,
showing an inhibition of 1862.1% and 4663.4% at 20 and 100 mM, respectively (* p,0.05).
doi:10.1371/journal.pone.0109787.g004
Table 1. THDP-17 was administered orally after 12 h fasted mice.
Group N
Vehicle
(DMSO)
THDP-17
(mg/Kg) Deaths before Sacrificed 24 h
6 h 12 h
I 3 + 0 1 1 1
II 3 + 50 1 1 1
III 3 + 300 1 1 1
IV 3 + 2000 2 1 –
Animals were divided in 4 groups and deaths after treatment were recorded.
doi:10.1371/journal.pone.0109787.t001
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present work, cytotoxicity of a 24 h-exposure to selected inhibitors
was evaluated in Caco-2 cells using the MTT method developed
by Mosmann [30] and modified by Denizot and Lang [31]. Based
on cell viability the inhibitors THDP-41, THDP-42 and THDP-
43 were rejected due to their high toxicity and the remaining
compounds (THDP-17, THDP-33 and THDP-39) were selected
for further inhibition studies.
- In vitro inhibition analysis. To evaluate the performance
of the PAG-inhibitors THDP-17, THDP-33 and THDP-39 we
used swine K-PAG (from kidney) in an in vitro optimised kinetic
assay with and without the addition of the inhibitors. First,
increasing concentration of inhibitors (ranging from 1 mM to
10 mM) were added to standard and optimized enzymatic assay
conditions with 99 mmol/l glutamine, 150 mmol/l phosphate and
100 mg K-PAG (Figure 1). THDP-33 and THDP-39 were able to
inhibit PAG completely at 10 mM. IC50 values were
19.161.3 mM for THPD-33, 31.662.7 mM for THDP-39 and
3.960.1 mM for THDP-17, indicating that THPD-33 and
THPD-39 were less powerful inhibitors than THDP-17. THDP-
33 and THDP-39 were able to completely inhibit PAG activity at
low milimolar level (Figure 1) which can be harmful for the
enterocyte, being discarded for future analysis.
THDP-17, N-(3-methyl-3-butenyl)-N9-phenylthiourea (Fig-
ure 2), was selected because it did not show cytotoxicity in cell
culture, and because it inhibits PAG activity partially at low
milimolar concentrations. In fact, there is a plateau (the enzyme
activity is no longer affected by increasing the inhibitor
concentration). This finding is highly relevant, since partial
inhibition of PAG could be beneficial for the reduction of
ammonia and the excess of glutamate production in the
management of HE, without affecting the viability of the
enterocyte.
PAG kinetic parameters were analyzed in absence and presence
of THDP-17, at different concentrations (1 and 10 mM), under
optimal analytical conditions, at different glutamine concentration
(0 to 200 mM). A lineal double reciprocal plot (1/v against 1/
[Gln]) in absence and presence of the inhibitor (Figure 3) shows
that the Vmax and KM values for PAG were 0.67 mmol min
-1, and
19.33 mM, respectively, indicating that in presence of the
inhibitor THDP-17 both parameters changes: Vmax-ap = 0.38 m-
mol min21, and KM-ap = 13.62 mM). Data show an uncompetitive
inhibition model indicating that THDP-17 binds PAG at a site
created after enzyme-substrate complex formation. We propose
that THDP-17 is a not-pure-uncompetitive inhibitor because the
Ki value obtained from Vmax-ap and KM-ap (23.2 mM and
40.5 mM, respectively) is different.
- in vivo inhibition. Since in vitro inhibition by THDP-17
does not guarantee that the inhibitor also works in vivo, we
evaluated the production of ammonia and glutamate from
glutamine by enterocyte cells (Caco-2) in the presence and
absence of THDP-17 at different concentrations (0, 5, 20 and
100 mM). Glutamate concentration was determined by HLPC in
the supernatants and the presence of THDP-17 in the cells was
analyzed by HPLC-MS. Results are shown on Figure 4. These
data indicate that PAG inhibition by THDP-17 in cell cultures is
effective at a concentration higher than 5 mM, showing an
inhibition of 1862.1% and 4663.4% at 20 and 100 mM,
respectively. This fact can be explained assuming that the inhibitor
can diffuse or transported through the plasma and the outer
mitochondrial membranes, reaching the PAG located at the inner
mitochondrial membrane, interfering its function and lowering its
activity. Since there is no direct evidence that this transport is
taking place, we have studied the evolution of the concentration of
THDP in the medium along the cultivation period, showing that
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56% and 72% of the inhibitor is diffused or transported into the
cells at 20 and 100 mM, respectively.
- Acute Toxicity of THDP17. Although THDP-17 did not
show any cytotoxic effect in cell cultures, we have studied the effect
of this compound in vivo using an animal model (C57BL mice)
since thiourea-derived compounds can be toxic in vivo [32]. Two
different assays were carried out: first, THDP-17 was administered
orally after 12 h fasted. In this case deaths were observed at 6, 12
and 24 h in all groups (Table-1), including control group (without
THDP-17) where only vehicle (DMSO) was administered.
Figure 5. Metformin inhibits glutaminase activity in a dose dependent manner: from 17.5% at 10 mM up to 68% at 100 mM (A) (*
p,0.05). This effect, analyzed by Dixon plot, showed competitive inhibition kinetics, with a Ki of 14.28 mM (B). In Caco2 cells, metformin 20 mM
showed 24% inhibition of glutaminase activity at 72 hours compared to control cultures (p,0.05) (glutamate production was decreased from
26.8560.74 mM to 19.962.05 mM; p,0.05) (C).
doi:10.1371/journal.pone.0109787.g005
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However, lethality of DMSO-treated mice did not differ signifi-
cantly in its lethality as compared to the groups treated with
THDP-17. The undiluted compound has low systemic toxicity but
a marked local necrotizing and inflammatory effect when it is
administered orally. Animals showed gastrointestinal ulcers and
duodenum bleeding (Figure S1). There were few fluctuations in
histopathological values but no changes appear to be drug-related
or of significance. No essential or histopathological damages were
seen in mice treated with THDP-17 including lungs, heart or liver
when compared to DMSO alone. We interpreted these results as
DMSO and/or THDP-17 was toxic for the animals in fasted state.
Therefore, we repeat the assay using feed animals. THDP-17 and/
or DMSO were then administered orally to animals after free
access to food and water overnight, and mice were sacrificed at
24 h and 72 h randomly. In this case, no deaths were observed
during the experimental period (Table 2); probably due to
protective effect of food. Macroscopic organs analysis from
animals sacrificed at 24 and 72 h showed gastrointestinal ulcers
and duodenum bleeding, although less pronounced than in the
case of the first group (fasted group).
These results demonstrate that THDP-17 is no toxic in vivo
and suggest that DMSO enhanced the toxicity of THDP in mice.
Therefore, this compound is currently used as a primary group for
the synthesis amphiphilic derivatives.
ii) Products currently used in HE therapy
A second group of compounds integrated by drugs habitually
used in the treatment of HE was also tested for glutaminase
inhibition: metformin, metronidazole, neomicine, rifaximin, lac-
tulose and lactitol. PAG activity inhibition was analyzed using
10 mM concentration. PAG activity in vitro was no affected by
neomycin, lactitol and lactulose, rather, an increased activity was
observed.
Since metformin seems to be protective against hepatic
encephalopathy in diabetic cirrhotic patients [33], we decided to
analyze in vitro PAG inhibition by metformin. Results in Figure-5
show that PAG was inhibited in a dose dependent manner: from
17.5% at 10 mM up to 68% at 100 mM. This effect, analyzed by
Dixon plot, showed competitive inhibition kinetics, with a Ki of
14.28 mM (Figure 5B). In Caco2 cells, metformin 20 mM showed
24% inhibition of glutaminase activity at 72 hours compared to
control cultures (p,0.05) (glutamate production was decreased
from 26.8560.74 mM to 19.962.05 mM; p,0.05) (Figure-5C).
Higher metformin concentrations (50, 100 and 200 mM) did not
yield higher inhibition rates. These results demonstrated that
metformin could serve as a new therapeutic option for HE
management, although THDP17 was able to inhibit glutaminase
(4663.4%) in a higher extent.
Conclusions
The major findings in this work are: i) although THDP-17 was
reported first in 1960, this is the first time that its use as
glutaminase activity inhibitor is described. THDP17 shows a
partial uncompetitive inhibition in vitro and a significant reduc-
tion of ammonia and glutamate production in vivo. Therefore,
THDP-17 could be a good candidate for HE management by
lowering ammonia production. ii) Moreover, we have shown that
metformin, an insulin sensitizer drug used for diabetes therapy,
could also inhibit PAG activity, resulting in new therapeutic option
for HE by reducing splenic ammonia production.
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C- Stomach.
(TIF)
Author Contributions
Conceived and designed the experiments: JAC JDB MDH IP FIG JMV.
Performed the experiments: MDH JAC IP JMV. Analyzed the data: JDB
JAC FIG MRG. Contributed reagents/materials/analysis tools: FIG JMV
FJM MRG. Contributed to the writing of the manuscript: JAC MDH JDB
FIG FJM MRG. Contributed dataset: PCA.
References
1. Zemtsova I, Go¨rg B, Keitel V, Bidmon HJ, Schro¨r K, et al. (2011) Microglia
activation in hepatic encephalopathy in rats and humans. Hepatology 54: 204–
15.
2. Llansola M, Montoliu C, Cauli O, Herna´ndez-Rabaza V, Agustı´ A, et al. (2013)
Chronic hyperammonemia, glutamatergic neurotransmission and neurological
alterations. Metab Brain Dis., 28: 151–154.
3. Jover-Cobos M, Noiret L, Lee K, Sharma V, Habtesion A, et al. (2014)
Ornithine phenylacetate targets alterations in the expression and activity of
glutamine synthase and glutaminase to reduce ammonia levels in bile duct
ligated rats. J Hepatol. 60: 545–53.
4. Dam G, Keiding S, Munk OL, Ott P, Vilstrup H, et al. (2013) Hepatic
encephalopathy is associated with decreased cerebral oxygen metabolism and
blood flow, not increased ammonia uptake. Hepatology, 57: 258–265.
5. Romero-Go´mez M, Bautista JD, Grande L, Ramos Guerrero RM, Sanchez
Munoz D. (2004) New concepts in the physiopathology of hepatic encephalop-
athy and therapeutic prospects. Gastroenterol Hepatol. 27: 40–8.
6. Nance FC., Kline DG (1971). Eck’s fistula encephalopathy in germ-free dogs.
Ann Surg. 174: 856–61.
7. Warren KS, Newton WL (1959) Portal and peripheral blood ammonia
concentrations in germ-free and conventional guinea pigs. Am J Pysiol. 197:
717–20.
8. Weber FJL, Veach GL (1979) The importance of the small intestine in gut
ammonium production in the fasting dog. Gastroenterology 77: 235–40.
9. Olde-Damink SW, Jalan R, Redhead DN., Hayes PC, Deutz NE, et al. (2002)
Inter-organ ammonia and amino acid metabolismo in metabolically stable
patients with cirrhosis and a TIPSS. Hepatology 36; 1163–71.
10. Romero-Go´mez M, Ramos-Guerrero R, Grande L, de Tera´n LC, Corpas R, et
al. (2004). Intestinal glutaminase activity is increased in liver cirrhosis and
correlates with minimal hepatic encephalopathy. J Hepatol, 41: 49–54.
11. Albrecht J, Norenberg MD (2006) Glutamine: a Trojan horse in ammonia
neurotoxicity. Hepatology 44: 788–94.
12. Olalla L, Gutie´rrez A, Campos JA, Khan ZU, Segura JA, et al. (2002) Nuclear
localization of L-type glutaminase in mammalian brain. J Biol Chem 277:
28939–38944.
13. Castell L, Vance C, Abbott R, Ma´rquez J, Eggleton P (2004) Granule
localization of glutaminase in human neutrophils and the consequence of
glutamine utilization for neutrophil activity. J Biol Chem 279: 13305–10.
14. Pe´rez-Go´mez C, Campos-Sandoval JA., Alonso FJ, Segura JA., Manzanares E.,
et al. (2005) Co-expression of glutaminase K and L isoenzymes in human
tumour cells. Biochem J 385: 535–542.
15. Roberg BA, Torgner IA, Kvamme E (2010) Kinetics of a novel isoform of
phosphate activated glutaminasa (PAG) in SH.SY5Y neuroblastoma cells.
Neurochem Res 35: 875–80.
16. Romero-Go´mez M, Jover M, Del Campo JA, Royo JL, Hoyas E, et al. (2010)
Variations in the promoter region of the glutaminase gene and the development
of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern
Med.153: 281–288.
17. James LA, Lunn PG, Middleton S, Elia M (1998) Distribution of glutaminase
and glutamine synthase activities in the human gastrointestinal tract. Clin Sci.
94: 313–19.
18. James LA, Lunn PG, Elia M (1988) Glutamine metabolism in the
gastrointestinal tract of the rat assessed by the relative activity of glutaminase
(EC 3.5.1.2) and glutamine synthetase (EC 6.3.1.2). Br J Nutrition. 79: 365–72.
19. Butterwort RF, Norenberg MD, Felipo V, Ferenci P, Albrecht J, et al. (2009)
Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int
29: 783–788.
20. Hawkins RA, Jessy J, Mans AM, Chedid A, DeJoseph MR (1994) Neomycin
reduces the intestinal production of ammonia from glutamine. Adv Exp Med
Biol. 368: 125–34.
21. Vega-Pe´rez JM, Perin˜a´n I, Argandon˜a M, Vega-Holm M, Palo-Nieto C, et al.
(2012) Isoprenyl-thiourea and urea derivatives as new farnesyl diphosphate
A New Inhibitor (THDP17) for Hepatic Encephalophathy
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e109787
analogues: synthesis and in vitro antimicrobial and cytotoxic activities. Eur J
Med Chem. 58: 591–612.
22. Iliceto A, Fava A, Mazzucato U, Radici P (1960) Allyl and benzhydryl
thiocyanates and isothiocyanates; thiocyanate-isothiocyanate equilibrium. Gaz-
zetta Chimica Italiana, 90: 919–40.
23. Furdik M., Sutoris V (1961) Synergists of pyrethrum. VI. Synthesis of endo-cis-
N-substituted 7-diphenylmethylenebicyclo[1.2.2]hept-5-ene-2,-3-dicarboxi-
mides. Chemicke Zvesti, 15: 173–80.
24. Heini HG, Gebhardt R, Brecht A, Mecke D (1987) Purification and
characterization of rat liver glutaminasa. Eur J Biochem 162: 541–546.
25. Shapiro RA, Haser WG, Curthoys NP (1985) The orientation of phosphate-
dependent glutaminasa on the inner membrane of rat renal mitochondria. Arch
Biochem Bioph 243: 1–7.
26. Lund P (1988) L-glutamine and L-glutamate: UV-method with glutaminasa and
glutamate dehydrogenase, in: H.U. Bermeyer (Eds.), Methods of enzymatic
analysis, Weinheim, 57–363.
27. Bradford MM (1976) Rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye binding.
Anal Biochem 72: 248–254.
28. Zhang SZ, Lipsky MM, Trump BF, Hsu IC (1990) Neutral red (NR) assay for
cell viability and xenobiotic-induced cytotoxicity in primary cultures of human
and rat hepatocytes. Cell Biol Toxicol. 6: 219–34.
29. Spielmann H, Genschow E, Leibsch M, Halle W (1999) Determination of the
starting dose for acute oral toxicity (LD50) testing in the up and down procedure
(UDP) from cytotoxicity data. Alternatives to Laboratory Animals 27: 957–966.
30. Mossman T (1983) Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assay. J. Immunol. Methods 65: 55–
63.
31. Denizot F, Lang R (1986) Rapid colorimetric assay for cellular growth and
survival. Modifications to the tetrazolium dye procedure giving improved
sensitivity and reliability. J. Immunol. Methods 89: 271–277.
32. Smith PB, Crespi C (2002) Thiourea toxicity in mouse C3H/10T12 cells
expressing human flavin-dependent monooxigenase 3. Biochemical Pharmacol-
ogy, 63: 1941–1948.
33. Ampuero J, Ranchal I, Nun˜ez D, Dı´az-Herrero MM, Maraver M, et al. (2012)
Metformin Inhibits Glutaminase Activity and Protects against Hepatic
Encephalopathy. PLoS One 7: e49279.
A New Inhibitor (THDP17) for Hepatic Encephalophathy
PLOS ONE | www.plosone.org 8 October 2014 | Volume 9 | Issue 10 | e109787
